BRPI0920651A2 - moduladores para amiloide beta - Google Patents
moduladores para amiloide betaInfo
- Publication number
- BRPI0920651A2 BRPI0920651A2 BRPI0920651A BRPI0920651A BRPI0920651A2 BR PI0920651 A2 BRPI0920651 A2 BR PI0920651A2 BR PI0920651 A BRPI0920651 A BR PI0920651A BR PI0920651 A BRPI0920651 A BR PI0920651A BR PI0920651 A2 BRPI0920651 A2 BR PI0920651A2
- Authority
- BR
- Brazil
- Prior art keywords
- beta amyloid
- amyloid modulators
- modulators
- beta
- amyloid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08166228 | 2008-10-09 | ||
PCT/EP2009/062570 WO2010040661A1 (en) | 2008-10-09 | 2009-09-29 | Modulators for amyloid beta |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0920651A2 true BRPI0920651A2 (pt) | 2016-01-12 |
Family
ID=41278679
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0920651A BRPI0920651A2 (pt) | 2008-10-09 | 2009-09-29 | moduladores para amiloide beta |
Country Status (14)
Country | Link |
---|---|
US (3) | US20100093731A1 (pt) |
EP (1) | EP2334665B1 (pt) |
JP (1) | JP5502089B2 (pt) |
KR (1) | KR101324414B1 (pt) |
CN (1) | CN102177151A (pt) |
AR (1) | AR073794A1 (pt) |
AU (1) | AU2009301210B2 (pt) |
BR (1) | BRPI0920651A2 (pt) |
CA (1) | CA2736924C (pt) |
ES (1) | ES2429517T3 (pt) |
IL (1) | IL210078A (pt) |
MX (1) | MX2011003246A (pt) |
TW (1) | TW201022249A (pt) |
WO (1) | WO2010040661A1 (pt) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8637525B2 (en) | 2009-07-31 | 2014-01-28 | Bristol-Myers Squibb Company | Compounds for the reduction of beta-amyloid production |
TWI468402B (zh) | 2009-07-31 | 2015-01-11 | 必治妥美雅史谷比公司 | 降低β-類澱粉生成之化合物 |
WO2012131539A1 (en) | 2011-03-31 | 2012-10-04 | Pfizer Inc. | Novel bicyclic pyridinones |
UA110688C2 (uk) | 2012-09-21 | 2016-01-25 | Пфайзер Інк. | Біциклічні піридинони |
NO3004079T3 (pt) * | 2013-06-04 | 2018-06-16 | ||
EP3253755B1 (en) | 2015-02-03 | 2020-08-26 | Pfizer Inc | Novel cyclopropabenzofuranyl pyridopyrazinediones |
KR102641048B1 (ko) * | 2017-06-26 | 2024-02-27 | 메르크 파텐트 게엠베하 | 치환된 질소 함유 복소환을 제조하는 방법 |
Family Cites Families (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG47583A1 (en) | 1986-01-13 | 1998-04-17 | American Cyanamid Co | 4,5,6-Substituted-n- (substituted-phenyl) -2- pyrimidinamines |
TW240163B (en) * | 1992-07-22 | 1995-02-11 | Syngenta Participations Ag | Oxadiazine derivatives |
US5387595A (en) | 1992-08-26 | 1995-02-07 | Merck & Co., Inc. | Alicyclic compounds as tachykinin receptor antagonists |
US5707622A (en) * | 1994-03-03 | 1998-01-13 | Genentech, Inc. | Methods for treating ulcerative colitis |
EA000992B1 (ru) | 1995-12-14 | 2000-08-28 | Мерк Энд Ко., Инк. | Антагонисты гормона, высвобождающего гонадотропин |
ATE288904T1 (de) | 1998-06-18 | 2005-02-15 | Bristol Myers Squibb Co | Durch kohlenstoff substituierte aminothiazole als inhibitoren von zyclin-abhägigen kinasen |
WO2000025780A1 (en) | 1998-10-29 | 2000-05-11 | Bristol-Myers Squibb Company | Compounds derived from an amine nucleus that are inhibitors of impdh enzyme |
US6596747B2 (en) * | 1998-10-29 | 2003-07-22 | Bristol-Myers Squibb Company | Compounds derived from an amine nucleus and pharmaceutical compositions comprising same |
SE9803773D0 (sv) | 1998-11-05 | 1998-11-05 | Astra Pharma Prod | Compounds |
GB9914258D0 (en) | 1999-06-18 | 1999-08-18 | Celltech Therapeutics Ltd | Chemical compounds |
EP1201661A4 (en) | 1999-07-15 | 2002-10-23 | Sumitomo Pharma | HETEROAROMATIC RING CONNECTIONS |
IL150420A0 (en) | 1999-12-28 | 2002-12-01 | Pharmacopeia Inc | Pyrimidine and triazine kinase inhibitors |
WO2001087845A2 (en) | 2000-05-15 | 2001-11-22 | Fujisawa Pharmaceutical Co., Ltd. | N-containing heterocyclic compounds and their use as 5-ht antagonists |
PT1355889E (pt) | 2000-12-22 | 2006-09-29 | Ortho Mcneil Pharm Inc | Derivados diamina triazole substituidos como inibidores de cinase |
IL159041A0 (en) | 2001-06-28 | 2004-05-12 | Smithkline Beecham Plc | N-aroyl cyclic amine derivatives as orexin receptor antagonists |
WO2003040141A1 (en) | 2001-09-28 | 2003-05-15 | Bayer Pharmaceuticals Corporation | Oxazolyl-phenyl-2,4-diamino-pyrimidine compounds and methods for treating hyperproliferative disorders |
FR2833948B1 (fr) | 2001-12-21 | 2004-02-06 | Sod Conseils Rech Applic | Nouveaux derives de benzimidazole et leur utilisation en tant que medicament |
PT1479397E (pt) * | 2002-02-05 | 2011-09-01 | Astellas Pharma Inc | Derivados de 2,4,6-triamino-1,3,5-triazina |
ATE529110T1 (de) * | 2002-03-05 | 2011-11-15 | Transtech Pharma Inc | Mono- und bicyclische azolderivate die die interaktion von liganden mit rage hemmen |
AU2003231231A1 (en) | 2002-05-06 | 2003-11-11 | Bayer Pharmaceuticals Corporation | Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders |
EP1601666A2 (en) * | 2002-07-02 | 2005-12-07 | Schering Corporation | New neuropeptide y y5 receptor antagonists |
CA2515068A1 (en) | 2003-02-03 | 2004-08-19 | Cv Therapeutics Inc. | Partial and full agonists of a1 adenosine receptors |
WO2004087699A2 (en) | 2003-03-25 | 2004-10-14 | Vertex Pharmaceuticals Incorporated | Thiazoles useful as inhibitors of protein kinases |
JP4847868B2 (ja) | 2003-05-14 | 2011-12-28 | ニューロジェネティック ファーマシューティカルズ、 インコーポレイテッド | 化合物、及び、アミロイドベータの調節におけるその使用 |
WO2005003103A2 (en) * | 2003-06-30 | 2005-01-13 | Astrazeneca Ab | 2, 4, 6-tri-substituted 6-membered heterocycles and their use in the treatment of neurodegenerative diseases |
DK1663242T3 (da) | 2003-08-07 | 2011-08-01 | Rigel Pharmaceuticals Inc | 2,4-Pyrimidindiamin-forbindelser og anvendelse som antiproliferative midler |
JP2007508260A (ja) | 2003-10-09 | 2007-04-05 | アクテリオン ファマシューティカルズ リミテッド | 新規なテトラヒドロピリジン誘導体 |
CN1871208A (zh) | 2003-10-30 | 2006-11-29 | 默克公司 | 作为大麻素受体调节剂的芳烷基胺 |
CA2550891A1 (en) | 2003-12-24 | 2005-07-14 | Bayer Cropscience Gmbh | Plant growth regulation |
US7649002B2 (en) | 2004-02-04 | 2010-01-19 | Pfizer Inc | (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists |
US7880009B2 (en) * | 2004-05-26 | 2011-02-01 | Eisai R&D Management Co., Ltd. | Cinnamide compound |
ATE387202T1 (de) | 2004-10-15 | 2008-03-15 | Glaxo Group Ltd | Pyrrolidinderivate als histaminrezeptor-liganden |
BRPI0516915A (pt) | 2004-12-01 | 2008-03-11 | Devgen Nv | derivados de tiazol substituìdos por 5-carboxamido que interagem com canais de ìons, particularmante com canais de ìons da famìlia kv |
US20060241038A1 (en) | 2005-04-20 | 2006-10-26 | Eisai Co., Ltd. | Therapeutic agent for Abeta related disorders |
NZ592990A (en) | 2005-11-01 | 2013-01-25 | Targegen Inc | Bi-aryl meta-pyrimidine inhibitors of kinases |
WO2007051333A1 (en) * | 2005-11-02 | 2007-05-10 | Oncalis Ag | Triazine beta-secretase inhibitors |
WO2007054480A1 (en) | 2005-11-08 | 2007-05-18 | N.V. Organon | 2-(benzimidazol-1-yl)-acetamide biaryl derivatives and their use as inhibitors of the trpv1 receptor |
US20090270623A1 (en) | 2005-11-18 | 2009-10-29 | Naoyuki Shimomura | Process for production of cinnamide derivative |
JPWO2007058304A1 (ja) | 2005-11-18 | 2009-05-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | シンナミド化合物の塩またはそれらの溶媒和物 |
US20070117839A1 (en) * | 2005-11-24 | 2007-05-24 | Eisai R&D Management Co., Ltd. | Two cyclic cinnamide compound |
TWI370130B (en) | 2005-11-24 | 2012-08-11 | Eisai R&D Man Co Ltd | Two cyclic cinnamide compound |
MY144960A (en) * | 2005-11-24 | 2011-11-30 | Eisai R&D Man Co Ltd | Morpholine type cinnamide compound |
WO2007120333A2 (en) | 2005-12-16 | 2007-10-25 | Genentech, Inc. | Tetracyclic kinase inhibitors |
WO2007076161A2 (en) | 2005-12-27 | 2007-07-05 | Myriad Genetics, Inc | Compounds with therapeutic activity |
TWI378091B (en) * | 2006-03-09 | 2012-12-01 | Eisai R&D Man Co Ltd | Multi-cyclic cinnamide derivatives |
WO2007102580A1 (ja) | 2006-03-09 | 2007-09-13 | Eisai R & D Management Co., Ltd. | 多環式シンナミド誘導体 |
SI1874781T1 (sl) | 2006-04-19 | 2009-12-31 | Boehringer Ingelheim Int | Dihidrotienopirimidini za zdravljenje vnetnih obolenj |
ATE480525T1 (de) | 2006-05-12 | 2010-09-15 | Ab Science | Neues verfahren zur synthese von 2- aminooxazolverbindungen |
AU2007252644A1 (en) | 2006-05-19 | 2007-11-29 | Eisai R & D Management Co., Ltd. | Heterocyclic type cinnamide derivative |
WO2007135969A1 (ja) | 2006-05-19 | 2007-11-29 | Eisai R & D Management Co., Ltd. | ウレア系-シンナミド誘導体 |
JP2009184924A (ja) | 2006-05-31 | 2009-08-20 | Eisai R & D Management Co Ltd | 生物学的試薬用化合物 |
US20080027001A1 (en) | 2006-07-07 | 2008-01-31 | Andrew Wood | Nogo receptor functional motifs, peptide mimetics, and mutated functional motifs related thereto, and methods of using the same |
SA07280403B1 (ar) | 2006-07-28 | 2010-12-01 | إيساي أر أند دي منجمنت كو. ليمتد | ملح رباعي لمركب سيناميد |
ATE496043T1 (de) | 2006-12-01 | 2011-02-15 | Actelion Pharmaceuticals Ltd | 3-heteroaryl (amino bzw. amido)-1- (biphenyl bzw. phenylthiazolyl) carbonylpiperdinderivate als orexinrezeptor-inhibitoren |
EP2117311A4 (en) | 2007-02-08 | 2011-05-11 | Merck Sharp & Dohme | THERAPEUTICS |
WO2008099210A2 (en) | 2007-02-12 | 2008-08-21 | Merck & Co., Inc. | Piperazine derivatives for treatment of ad and related conditions |
EP2120573A4 (en) | 2007-02-12 | 2011-05-25 | Merck Sharp & Dohme | DERIVATIVES OF PIPERIDINE |
DE102007010801A1 (de) | 2007-03-02 | 2008-09-04 | Bayer Cropscience Ag | Diaminopyrimidine als Fungizide |
EP2155740B1 (en) | 2007-05-11 | 2011-01-26 | F. Hoffmann-La Roche AG | Hetarylanilines as modulators for amyloid beta |
WO2008156580A1 (en) | 2007-06-13 | 2008-12-24 | Merck & Co., Inc. | Triazole derivatives for treating alzheimer's disease and related conditions |
PT2200436E (pt) | 2007-09-04 | 2015-04-29 | Scripps Research Inst | Pirimidinilaminas substituídas como inibidoras da proteína quinase |
CN101848897A (zh) | 2007-09-06 | 2010-09-29 | 先灵公司 | γ分泌酶调节剂 |
CA2708151A1 (en) | 2007-12-11 | 2009-06-18 | Schering Corporation | Gamma secretase modulators |
JP5395808B2 (ja) * | 2007-12-21 | 2014-01-22 | エフ.ホフマン−ラ ロシュ アーゲー | オレキシン受容体アンタゴニストとしてのヘテロアリール誘導体 |
US7923450B2 (en) * | 2008-01-11 | 2011-04-12 | Hoffmann-La Roche Inc. | Modulators for amyloid beta |
WO2009103652A1 (en) | 2008-02-22 | 2009-08-27 | F. Hoffmann-La Roche Ag | Modulators for amyloid beta |
EP2288260A4 (en) | 2008-06-20 | 2013-10-23 | Genentech Inc | TRIAZOLOPYRIDINE-JAK HEMMER COMPOUNDS AND METHOD |
WO2010010184A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors |
WO2010010188A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases. |
TWI453207B (zh) | 2008-09-08 | 2014-09-21 | Signal Pharm Llc | 胺基三唑并吡啶,其組合物及使用其之治療方法 |
TW201035101A (en) | 2009-02-26 | 2010-10-01 | Eisai R&D Man Co Ltd | Nitrogen-containing fused heterocyclic compound |
-
2009
- 2009-09-29 KR KR1020117006396A patent/KR101324414B1/ko active IP Right Grant
- 2009-09-29 JP JP2011529527A patent/JP5502089B2/ja not_active Expired - Fee Related
- 2009-09-29 ES ES09783515T patent/ES2429517T3/es active Active
- 2009-09-29 EP EP09783515.1A patent/EP2334665B1/en active Active
- 2009-09-29 BR BRPI0920651A patent/BRPI0920651A2/pt not_active Application Discontinuation
- 2009-09-29 AU AU2009301210A patent/AU2009301210B2/en not_active Ceased
- 2009-09-29 WO PCT/EP2009/062570 patent/WO2010040661A1/en active Application Filing
- 2009-09-29 CN CN2009801398244A patent/CN102177151A/zh active Pending
- 2009-09-29 MX MX2011003246A patent/MX2011003246A/es active IP Right Grant
- 2009-09-29 CA CA2736924A patent/CA2736924C/en not_active Expired - Fee Related
- 2009-10-02 US US12/572,327 patent/US20100093731A1/en not_active Abandoned
- 2009-10-08 AR ARP090103868A patent/AR073794A1/es unknown
- 2009-10-08 TW TW098134150A patent/TW201022249A/zh unknown
-
2010
- 2010-12-16 IL IL210078A patent/IL210078A/en active IP Right Grant
-
2012
- 2012-04-02 US US13/437,057 patent/US8389717B2/en active Active
-
2013
- 2013-01-04 US US13/733,924 patent/US20130143883A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20100093731A1 (en) | 2010-04-15 |
US20130143883A1 (en) | 2013-06-06 |
WO2010040661A1 (en) | 2010-04-15 |
US8389717B2 (en) | 2013-03-05 |
TW201022249A (en) | 2010-06-16 |
EP2334665A1 (en) | 2011-06-22 |
CN102177151A (zh) | 2011-09-07 |
JP5502089B2 (ja) | 2014-05-28 |
KR101324414B1 (ko) | 2013-11-01 |
MX2011003246A (es) | 2011-04-21 |
ES2429517T3 (es) | 2013-11-15 |
IL210078A (en) | 2014-08-31 |
AU2009301210B2 (en) | 2014-05-15 |
AU2009301210A1 (en) | 2010-04-15 |
CA2736924A1 (en) | 2010-04-15 |
AR073794A1 (es) | 2010-12-01 |
IL210078A0 (en) | 2011-02-28 |
EP2334665B1 (en) | 2013-07-10 |
KR20110052712A (ko) | 2011-05-18 |
JP2012504575A (ja) | 2012-02-23 |
US20120190682A1 (en) | 2012-07-26 |
CA2736924C (en) | 2016-06-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0907577A2 (pt) | Moduladores para amiloide beta | |
BRPI0906799A2 (pt) | Moduladores para amiloide beta | |
ATE496915T1 (de) | Hetarylaniline als modulatoren für amyloid beta | |
EP2367826A4 (en) | MODULATORS OF THE PROTEIN -AMYLOID | |
FI20085855A0 (fi) | Aaltojohtoelementti | |
BRPI0910459A2 (pt) | agentes nucleares para polihidroxialcanoatos | |
BRPI0812818A2 (pt) | Turbo-reator para aeronave | |
DK2512451T3 (da) | Modulator | |
BRPI1014262A2 (pt) | anticorpos específicos para caderina-17 | |
BRPI0909492A2 (pt) | dispositivo para produção de chocolate | |
BRPI0920651A2 (pt) | moduladores para amiloide beta | |
BRPI0907855A2 (pt) | Dispositivo para plastilhamento | |
BRPI0913033A2 (pt) | projeto de pad para mram-stt | |
ES1064958Y (es) | Soporte para mechero | |
ES1065835Y (es) | Caperuza para cetreria | |
ES1070148Y (es) | Macolla para barrotes mejorada | |
ES1067042Y (es) | Horca para la construccion | |
ES1065263Y (es) | Captafaros para bionda | |
ES1066482Y (es) | Pieza constructiva para paramento | |
ES1071124Y (es) | Parapente para aeromodelismo | |
ES1067384Y (es) | Estructura para montaje de expositores | |
ES1069058Y (es) | Entarimado para exteriores | |
ES1068567Y (es) | Capialzado para persianas | |
UY3851Q (es) | Habitaculo para meditación | |
ES1067955Y (es) | Banderola para señalizacion |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |